Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUK Nine b: OPTIMUM
ISRCTN16847817Phase 2Active, not recruiting
- Sponsor
- University of Leeds
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, bortezomib, lenalidomide, daratumumab, dexamethasone and 1 more in multiple myeloma (MM) and plasma cell malignancies, sponsored by University of Leeds. Primary endpoint: Primary efficacy endpoint. Started May 2017; status: active, not recruiting.
02
Drugs
cyclophosphamidebortezomiblenalidomidedaratumumabdexamethasone
03
Conditions
multiple myeloma (MM)plasma cell malignancies
Beyond the preview
Go deeper on ISRCTN16847817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16847817.